IDARUBICIN PLUS MELPHALAN CONDITIONING REGIMEN

摘要

There is described the use of idarubicin at dosages of from 12 to 17 mg/m<2> days 1-3 i.v. as continuous infusion, followed by Melphalan, 180 mg/m<2>, day 5, as a conditioning regimen for the treatment of cancers responsive to idarubicin such as multiple myeloma (MM), non Hodgkin lymphoma (NHL) and Hodgkin disease (HD). The regimen of the present invention is of great advantage because transplant is done at day +7.